Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 20/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 20/20 | 1.00 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7333083 | 0.97 | PDE3B (1.00) | PDE3BPDE3AP2RY12 | |
| SCHEMBL7325332 | 0.97 | PDE3B (1.00) | PDE3BPDE3AP2RY12 | |
| SCHEMBL7435833 | 0.88 | PDE3B (1.00) | PDE3BPDE3A | |
| SCHEMBL7432038 | 0.88 | PDE3B (1.00) | PDE3BPDE3A | |
| SCHEMBL7326865 | 0.88 | PDE3B (1.00) | PDE3BPDE3AP2RY12 | |
| Hydrochloric Acid SCHEMBL7432134 | 0.88 | PDE3B (1.00) | PDE3BPDE3A | |
| Hydrochloric Acid SCHEMBL7431968 | 0.88 | PDE3B (1.00) | PDE3BPDE3A | |
| SCHEMBL10657958 | 0.87 | PDE3B (1.00) | PDE3BPDE3AP2RY12 | |
| SCHEMBL7437588 | 0.87 | PDE3B (0.98) | PDE3BPDE3A | |
| Hydrochloric Acid SCHEMBL7445030 | 0.87 | PDE3B (0.98) | PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4943573-A | ENZYME INHIBITORS, CARDIOTONIC, ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1990-07-24 | — | — | US | claimed |
| EP-4706758-A2 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250171497-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | BAUSCH HEALTH IRELAND LIMITED (IE) | 2025-05-29 | — | — | US | disclosed |
| US-20250049881-A1 | FORMULATIONS OF GUANYLATE CYCLSE C AGONISTS AND METHODS OF USE | JPMORGAN CHASE BANK, N.A. | 2025-02-13 | — | — | US | disclosed |
| US-12146003-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2024-11-19 | — | — | US | disclosed |
| US-20240325487-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2024-10-03 | — | — | US | disclosed |
| EP-4424697-A2 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | Bausch Health Ireland Limited (IE) | 2024-09-04 | — | — | EP | disclosed |
| US-20240287137-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | JPMORGAN CHASE BANK, N.A. | 2024-08-29 | — | — | US | disclosed |
| EP-3004138-B1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | BAUSCH HEALTH IRELAND LTD (IE) | 2024-03-13 | — | — | EP | disclosed |
| EP-4309673-A2 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | Bausch Health Ireland Limited (IE) | 2024-01-24 | — | — | EP | disclosed |
| EP-0665023-B1 | MEDICAL MATERIAL AND PROCESS FOR PRODUCING THE SAME | OTSUKA PHARMA CO LTD (JP) | 2004-04-21 | — | — | EP | disclosed |
| EP-0859768-B1 | AMINE ACID SALT COMPOUNDS AND PROCESS FOR THE PRODUCTION THEREOF | YOO SEO HONG (US) | 2003-01-08 | — | — | EP | disclosed |
| EP-0859768-A4 | AMINE ACID SALT COMPOUNDS AND PROCESS FOR THE PRODUCTION THEREOF | YOO SEO HONG (US) | 1998-11-11 | — | — | EP | disclosed |
| EP-0859768-A1 | AMINE ACID SALT COMPOUNDS AND PROCESS FOR THE PRODUCTION THEREOF | Yoo, Seo Hong (US) | 1998-08-26 | — | — | EP | disclosed |
| US-5756553-A | Medical material and process for producing the same | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1998-05-26 | — | — | US | disclosed |
| US-5686588-A | Amine acid salt compounds and process for the production thereof | YOO SEO HONG (US) | 1997-11-11 | — | — | US | disclosed |
| WO-1997007112-A1 | AMINE ACID SALT COMPOUNDS AND PROCESS FOR THE PRODUCTION THEREOF | YOO SEO HONG (US) | 1997-02-27 | — | — | WO | disclosed |
| EP-0704223-A1 | METHOD OF INHIBITING BLOOD COAGULATION DURING EXTRACORPOREAL BLOOD CIRCULATION AND DEVICE FOR RELEASING ANTITHROMBOTIC DRUG USED THEREIN | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1996-04-03 | — | — | EP | disclosed |
| EP-0665023-A1 | MEDICAL MATERIAL AND PROCESS FOR PRODUCING THE SAME | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1995-08-02 | — | — | EP | disclosed |
| US-4943573-A | ENZYME INHIBITORS, CARDIOTONIC, ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1990-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12146003-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | PDE3B 5/4885PDE3A 6/4885P2RY12 1863/4885 |
| US-20250171497-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | PDE3B 5/4885PDE3A 6/4885P2RY12 1863/4885 |
| US-20240325487-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | PDE3B 554/4885PDE3A 409/4885P2RY12 1138/4885 |
| US-20240287137-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | PDE3B 5/4885PDE3A 6/4885P2RY12 1863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.